Leica Biosystems announces launch of Aperio VERSA scanner at AACR annual meeting

Leica Biosystems announces the introduction of the Aperio VERSA, a combination digital pathology research scanner for brightfield, fluorescence and FISH imaging at the American Association for Cancer Research (AACR) annual meeting in Philadelphia, opening on April 18th, 2015.

The Aperio VERSA is the latest addition to the Aperio scanner family, with an optimized optical pathway and dedicated detection for both brightfield and fluorescence. High levels of automation and an optional 200 slide autoloader enable unsupervised batch processing, from low magnification to high resolution, oil-immersion scanning.

In addition, Leica Biosystems will unveil a new ISH algorithm and the latest version of Aperio eSlide Manager. The ISH algorithm is for the detection and quantification of single or dual brightfield in-situ hybridization markers. It is optimized for samples stained on the BOND RX, Leica Biosystems fully automated research advanced staining platform. Scanned slides can be accessed via the Aperio
eSlide Manager web or client viewers, which enable the optimal, high-speed viewing experience for multi-channel, z-stack fluorescent images.

"The Aperio VERSA is a breakthrough for researchers searching for an affordable solution for their diverse imaging needs," said Puneet Sarin, vice president and general manager of Leica Biosystems' Pathology Imaging Business. "This combined introduction of solutions, from advanced staining, to imaging and computerized image analysis, demonstrates our commitment to provide cutting-edge technology to drive new breakthroughs in biomarker discovery. We see the Aperio VERSA and research software as valuable tools for core laboratories, bringing increased efficiency and quality to research."

Source:

Leica Biosystems

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Artificial intelligence predicts the risk of metastatic relapse in breast cancer patients